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Abstract (149 words) 1 
 Opioid-induced constipation has a negative impact on quality of life for patients 2 
with chronic pain and can affect more than a third of patients. A related but separate 3 
entity is postoperative ileus, which is an abnormal pattern of gastrointestinal motility 4 
after surgery. Non-selective μ-opioid receptor antagonists reverse constipation and 5 
opioid-induced ileus but cross the blood-brain barrier and may reverse analgesia. 6 
Peripherally acting μ-opioid receptor antagonists target the μ-opioid receptor without 7 
reversing analgesia. Three such agents are FDA-approved. We reviewed the literature for 8 
randomized, controlled trials that studied the efficacy of alvimopan, methylnaltrexone, 9 
and naloxegol in treating either opioid-induced constipation or postoperative ileus. 10 
Peripherally acting μ-opioid receptor antagonists may be effective in treating both opioid-11 
induced bowel dysfunction and postoperative ileus but definitive conclusions are not 12 
possible due to study inconsistency and the relatively low quality of evidence. 13 
Comparisons of agents are difficult due to heterogeneous endpoints and no head-to-head 14 
studies.  15 
 4 
Introduction 16 
Despite recent focus on the opioid epidemic millions of patients rely on opioids to 17 
treat their chronic pain.1 Opioid-related adverse drug effects are common, especially 18 
opioid-induced bowel dysfunction (OIBD), which is a spectrum of symptoms including 19 
dry mouth, nausea, vomiting, gastric stasis, bloating, abdominal pain, and opioid-induced 20 
constipation (OIC).2 OIC is especially prevalent, affecting up to 41% of patients taking 21 
long-term opioids.3 A working group of experts recently proposed that OIC be defined as 22 
a change when initiating opioid therapy from baseline bowel habits that is characterized 23 
by any of the following: reduced bowel movement frequency; development or worsening 24 
of straining to pass bowel movements; a sense of incomplete rectal evacuation; or harder 25 
stool consistency.4 26 
Postoperative ileus (POI) is a related but distinct entity from OIC that also 27 
involves loss of forward propulsive motion of the gut but in the perioperative setting. A 28 
standard POI definition does not exist in the literature, but the authors of one review 29 
suggest that it is “an abnormal pattern of gastrointestinal motility, most frequently 30 
occurring after abdominal surgery” and encompasses the “interval from surgery until 31 
passage of flatus/stool and tolerance of an oral diet.”5 POI has a multifactorial etiology 32 
that is shared with OIC, including the surgical stress response,6,7 the inflammatory 33 
response that accompanies bowel manipulation,6,7,8 and opioids that are both 34 
endogenously released by the GI tract7 and given by clinicians for intra- and 35 
postoperative analgesia.9 Most importantly, POI can be a driver of poor patient 36 
satisfaction, increase hospital length of stay, and increase overall hospital costs.10 37 
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Throughout the hospital physicians will likely encounter patients with one or both 38 
of these conditions and need a good working knowledge of the basic mechanisms and 39 
therapeutic options that are available to treat these relatively common pathophysiologic 40 
states. 41 
Conventional therapies, including fiber, opioid rotation, stool softeners, and 42 
laxatives, have limited data to support their use in OIC.11 They may be used initially with 43 
relatively low risk and minimal cost but are unlikely to effectively treat the symptoms 44 
alone. Non-specific opioid antagonists can reverse OIC and POI but may reverse 45 
analgesia as well.12 Drugs that specifically block the µ-opioid receptor outside of the 46 
central nervous system, collectively known as peripherally acting µ-opioid receptor 47 
(PAM-OR) antagonists, have been developed as a possible solution to this problem. 48 
PAM-OR antagonists specifically target the µ-opioid receptor in the peripheral nervous 49 
system and treat one of the major underlying mechanisms of both OIC and POI. In the 50 
United States three such drugs are approved for one of these two indications: alvimopan, 51 
methylnaltrexone, and naloxegol. 52 
Currently, alvimopan has approval from the Food and Drug Administration (FDA 53 
as a “peripherally acting µ-opioid receptor antagonist indicated to accelerate the time to 54 
upper and lower gastrointestinal recovery following partial large or small bowel resection 55 
surgery with primary anastomosis.”13 Methylnaltrexone was first approved as a 56 
subcutaneous injection “for the treatment of opioid-induced constipation in patients with 57 
advanced illness who are receiving palliative care, when response to laxative therapy has 58 
not been sufficient”14 and very recently was approved in the oral formulation for patients 59 
with chronic non-cancer pain and OIC.15 The most recent addition to the PAM-OR 60 
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antagonists, naloxegol, has been in clinical use since its approval in 2014 as “an opioid 61 
antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult 62 
patients with chronic non-cancer pain.”16 Several randomized trials involving PAM-OR 63 
antagonists have recently been published17,18; in addition, previous reviews have focused 64 
solely on a single agent19,20 or either OIC21 or POI22 but not both. Therefore, an update 65 
that discusses strengths and limitations of the evidence is warranted. We conducted a 66 
systematic review for randomized, placebo-controlled trials that compared alvimopan, 67 
methylnaltrexone, and naloxegol to placebo and had efficacy as the primary endpoint. 68 
The subsequent discussion will focus on the evidence for these PAM-OR antagonists in 69 
treating OIC and POI. 70 
 71 
 72 
 7 
Methods 73 
 We conducted the review protocol using the Preferred Reporting Items for 74 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines.23 During the months of 75 
April and May 2016 and again in February 2017, we conducted searches using PubMed 76 
and Scopus databases looking for randomized, placebo-controlled trials that studied the 77 
efficacy of alvimopan, methylnaltrexone, or naloxegol in patients with OIC or 78 
postoperative ileus. The last date searched was February 3, 2017. There were no date 79 
limitations placed on the searches in either database. We used the following search 80 
protocol in PubMed: (((“alvimopan”[Supplementary Concept] OR “alvimopan”[All 81 
Fields]) OR (“methylnaltrexone”[Supplementary Concept] OR “methylnaltrexone”[All 82 
Fields]) OR (“naloxegol”[Supplementary Concept] OR “naloxegol”[All Fields])) OR 83 
“peripheral opioid antagonist”[All Fields] OR “peripherally acting opioid antagonist”[All 84 
Fields] OR (peripheral[All Fields] AND mu[All Fields] AND antagonist[All Fields]) OR 85 
(peripheral[All Fields] AND mu[All Fields] AND (“narcotic 86 
antagonists”[Pharmacological Action] OR “narcotic antagonists”[MeSH Terms] OR 87 
(“narcotic”[All Fields] AND “antagonists”[All Fields]) OR “narcotic antagonists”[All 88 
Fields] OR (“opioid”[All Fields] AND “antagonist”[All Fields]) OR “opioid 89 
antagonist”[All Fields])) OR “opioid antagonist”[All Fields]) AND (“postoperative ileus” 90 
OR “opioid-induced bowel dysfunction”[All Fields] OR “opioid-induced 91 
constipation”[All Fields]).  92 
 Our search protocol for Scopus included the following: ( ALL ( alvimopan ) OR 93 
ALL ( methylnaltrexone ) OR ALL ( naloxegol ) OR ALL ( peripheral opioid 94 
antagonist ) OR ALL ( peripherally acting opioid antagonist ) OR ALL ( opioid 95 
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antagonist ) AND ALL ( opioid-induced bowel dysfunction ) OR ALL ( opioid-induced 96 
constipation ) OR ALL ( postoperative ileus ) ) AND DOCTYPE ( ar ) AND ( LIMIT-97 
TO(LANGUAGE,”English” ) ). 98 
 99 
Inclusion Criteria 100 
 Studies that were written in English involving clinical patients who had OIC and 101 
were being given either a PAM-OR antagonist or placebo or were given a PAM-OR 102 
antagonist or placebo for the purpose of treating or preventing POI were included. 103 
 104 
Exclusion Criteria 105 
 Studies that examined a PAM-OR antagonist in the setting of experimentally 106 
induced OIC (giving healthy volunteers codeine followed by a PAM-OR antagonist, for 107 
example) were extracted but included in a separate table and not included in the formal 108 
review. Studies that were prospective but did not include a placebo group were excluded, 109 
as were studies in which patients were not randomized. Also excluded were post-hoc or 110 
subset analyses of clinical trials that had been previously published. When applicable, 111 
only the blinded portion of a study was reviewed and analyzed. 112 
 113 
Review Protocol and Evidence Grading 114 
 Evidence quality was assessed using the Grades of Recommendation, Assessment, 115 
Development, and Evaluation (GRADE) approach (see Tables 1 and 2).24 Using this 116 
approach, studies are classified as high, moderate, low, or very low quality of evidence. 117 
 9 
 All articles were first reviewed independently by ES and AG and assessed for 118 
inclusion in the review. If the determination could not be made from reading the article 119 
title, the abstract was reviewed, and if ambiguity remained after that, the full article was 120 
subsequently downloaded and reviewed. Reference lists from screened articles were 121 
searched as well. Discrepancies were resolved by discussion between ES and AG. 122 
Articles that met all inclusion criteria but studied OIC treatment in healthy volunteers 123 
were not included in the formal review but are shown separately in Table 1.  124 
 125 
  126 
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Results 127 
Study Selection  128 
 Initial search of the literature yielded 1,314 articles (Figure 1). Screening of 129 
reference lists yielded two additional studies.25,26 One additional study that was initially 130 
excluded because it referred to alvimopan as ADL 8-2698, its investigational name, was 131 
later included in the review after confirming that it did in fact study alvimopan (Figure 132 
1).27 Because of the overlap between PubMed and Scopus databases, there were 158 133 
duplicates. Reasons for exclusion are shown in Figure 1. The two most common reasons 134 
for exclusion were that PAM-OR antagonists were not studied (n=588), which primarily 135 
applied to Scopus articles, and that the studies were not randomized, controlled trials 136 
(RCTs; n=459). A total of 23 studies were included in the final review. The four RCTs 137 
that enrolled healthy volunteers were grouped separately and are shown in Table 1.28-31 138 
 139 
Opioid-Induced Bowel Dysfunction Studies in Healthy Volunteers 140 
 Four Phase 1 studies enrolled healthy volunteers and administered a µ-opioid 141 
agonist to induce delay in gut transit and then administered a PAM-OR antagonist to 142 
evaluate its effects on gut transit time compared to placebo (Table 1).28-31 In the single 143 
study on alvimopan,30 12 mg was given along with codeine 30 mg four times a day and 144 
alvimopan reversed the codeine-induced delay in gut transit and improved gut transit in 145 
patients not given codeine as well.  146 
 In one of the studies that enrolled healthy volunteers who were given morphine 147 
and then randomly assigned to one of two doses of subcutaneous methylnaltrexone or 148 
placebo,29 both the 0.1 and 0.3 mg/kg doses reversed morphine-induced delay in gut 149 
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transit time. Wong et al, however, did not find any difference between subcutaneous 150 
methylnaltrexone 0.3 mg/kg and placebo in reducing the codeine-induced delay in gut 151 
transit.31 Yuan et al gave healthy volunteers intravenous methylnaltrexone 0.45 mg/kg 152 
after giving them morphine and found that methylnaltrexone prevented 97% of 153 
morphine-induced delay in gut transit time.28  154 
 155 
Opioid-Induced Constipation Studies 156 
 A total of 14 RCTs that studied PAM-OR antagonists in the setting of OIC were 157 
included in the review (Table 2). All alvimopan studies included patients with non-cancer 158 
pain who were given oral alvimopan in either a 0.5- or 1-mg dose. The primary outcome 159 
for two studies was the percentage of patients with at least three spontaneous bowel 160 
movements (SBMs) per week.32,33 One study’s primary outcome was the mean frequency 161 
of weekly SBMs34 and in another it was the percentage of patients that had a BM within 162 
eight hours.35 When analyzing the primary outcome of the four studies on alvimopan, 163 
three showed a positive result for the alvimopan group32,34,35 and one showed no 164 
difference.33 Study quality was low for all four studies. 165 
 The effects of alvimopan on µ-opioid receptors in the central nervous system 166 
were minimal. Three alvimopan studies reported no differences in pain scores or opioid 167 
consumption between study groups,32,33,34 while one study described two patients in the 168 
1-mg alvimopan group who had increases in pain but no difference between groups 169 
receiving the 0.5-mg dose.35  170 
 There were seven studies on methylnaltrexone for OIC.17,18,36-40 Four studies 171 
included patients with non-cancer pain only,18,36,39,40 while the other three enrolled 172 
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patients with both cancer and non-cancer pain.17,37,38 The selected dose for studies with 173 
subcutaneous methylnaltrexone was 12 mg in two studies,39,40 8 or 12 mg in one study,17 174 
0.15 mg/kg in one study, 0.15 or 0.3 mg/kg in one study,38 and up to 0.365 mg/kg in the 175 
study that used intravenous methylnaltrexone.36 The single study of oral 176 
methylnaltrexone included doses of 150, 300, and 450 mg.18 The primary outcome was 177 
positive in all seven studies. In five studies, the primary outcome was achievement of a 178 
spontaneous bowel movement (SBM) within 4 hours of receiving the study drug17,37-383940 179 
Another study had no primary endpoint but reported that laxation occurred within one 180 
minute of initiating methylnaltrexone intravenous infusion in 10 of 11 patients.36 In the 181 
single study of the oral formulation, the primary endpoint was the percentage of patients 182 
with a mean number of dosing days resulting in a SBM within four hours of dosing. 183 
Although this endpoint was greater in both 300- and 450-mg groups, it was lower than 184 
the response rate for the subcutaneous formulation.18 The 450-mg dose had highest 185 
efficacy without increasing adverse events. Study quality was moderate for two 186 
studies,17,18 low for three studies,37-3839 and very low for two studies.36,40  187 
 In five of the studies, analgesia was preserved based on no differences in pain 188 
scores, opioid consumption, or both between treatment groups.17,37-383940 For oral 189 
methylnaltrexone, pain scores did not change from baseline.18 In the remaining study, 190 
pain and opioid use were not assessed but patients reported no change in subjective 191 
withdrawal symptoms.36 In the largest study by Michna et al,39 rescue laxatives were used 192 
by 61.7% of the placebo group versus 38.7% in the daily dosing group and 41.7% in the 193 
every-other-day dosing group. 194 
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 There were two published articles for naloxegol, one of which described a study 195 
involving patients with cancer and non-cancer pain41 while the other studied only non-196 
cancer pain and consisted of two smaller trials.42 Both studies had positive outcomes for 197 
the primary outcome which was a greater number of SBMs per week for both 25- and 50-198 
mg doses in the article by Webster et al41 and accelerated time to first rescue-free bowel 199 
movement (RFBM) for 25 mg in both trials for Chey et al and 12.5 mg in one of two 200 
trials.42 Study quality was moderate for one study42 and low for the other.41 201 
 In both naloxegol studies, analgesia was preserved with no differences in pain 202 
scores or opioid consumption existing between study groups. The use of rescue laxatives 203 
was high in placebo and treatment groups for the study by Chey et al (72.0, 63.4, and 204 
54.7% in study 04 and 70.7, 57.3, and 57.3% in study 05).42 When comparing naloxegol 205 
to oral methylnaltrexone, 50% of patients who received 25 mg of naloxegol had a RFBM 206 
within six hours of the first dose, compared to approximately 30% of patients who 207 
received 450 mg of oral methylnaltrexone.18,41 However, the incidence of GI adverse 208 
events was greater for naloxegol than for oral methylnaltrexone. 209 
 210 
Postoperative Ileus Studies 211 
 A total of 10 studies on POI were included in the review (Table 3). Primary 212 
endpoints of the studies varied but most used the achievement of either GI-2 recovery 213 
(toleration of solid food and first bowel movement) or GI-3 recovery (toleration of solid 214 
food and flatus or first bowel movement). Of the eight studies that examined alvimopan, 215 
five enrolled patients who underwent major abdominal surgery,43-47 one included bowel 216 
resection,48 one included patients undergoing total abdominal hysterectomy,49 and one 217 
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included radical cystectomy.50 Aside from the study by Taguchi et al,43 which was a 218 
Phase I study, four of the other alvimopan studies examined both 6- and 12-mg doses,44-47 219 
while the remaining three only used 12 mg.48-50 These doses were three- to six-fold 220 
greater than the doses used for OIC. Of note, six alvimopan studies excluded chronic 221 
opioid users.43,45,46,47,48,49 Six studies reported positive results for the primary outcome of 222 
accelerated GI recovery (flatus, GI-2, or GI-3),43,44,45,48,49,50 while two alvimopan studies 223 
found no difference between groups,46,47 although Viscusi et al did report an accelerated 224 
time to GI-2 recovery (secondary endpoint) in the alvimopan group for both 6- and 12-225 
mg doses. Study quality was moderate for four studies,45-48 low for two,49,50 and very low 226 
for one.43 227 
 Analgesia was preserved in seven of the studies for all groups,43-50 with the 228 
exception of the 6-mg group in one study which demonstrated greater opioid 229 
consumption than placebo.44 230 
 Yu et al51 studied methylnaltrexone intravenously (IV) for POI at both 12- and 231 
24-mg doses in two identical, parallel-group studies for patients who underwent 232 
segmental colectomy. For the primary endpoint of time until first SBM, they found no 233 
difference between groups. They also found no difference among any secondary 234 
endpoints. Study quality was moderate. Preservation of analgesia was unclear because the 235 
authors did not report pain scores nor opioid consumption, although they stated that 236 
“there was no evidence that methylnaltrexone increased the requirement for opioids to 237 
relieve postsurgical pain.” Viscusi et al,26 in contrast, studied IV methylnaltrexone in the 238 
setting of POI and found that it accelerated time to first SBM; however, this study was 239 
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exploratory with a small sample size (n=65) that was not determined prior to patient 240 
enrollment. 241 
  242 
 243 
  244 
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Discussion 245 
 This review demonstrates that PAM-OR antagonists may be effective for OIC and 246 
POI without reversing opioid-mediated analgesia but study design inconsistency and 247 
variable endpoints makes definitive conclusions impossible. PAM-OR antagonists as a 248 
class prevent opioid-induced increases in gut transit time in healthy volunteers and 249 
provide specific, targeted treatment of OIC and POI that result from a loss of coordinated 250 
propulsive action in the gut due to opioids. 251 
 The studies reviewed ranged from very low to moderate quality according to the 252 
GRADE recommendations for rating study quality.24 There is especially a need for 253 
comparative studies that directly compare two or more of the three agents studied here. 254 
Heterogeneity in endpoints as well as study protocols was a problem throughout the 255 
literature. 256 
 Our results agree with the meta-analysis by Ford et al,21 who found that 257 
methylnaltrexone was more effective than placebo in treating OIC. While their analysis 258 
included six trials, ours included eight. They also concluded that alvimopan was superior 259 
to placebo for OIC and included four trials, as we did. They too noted considerable 260 
heterogeneity among studies, more so with methylnaltrexone. Subsequent pooled 261 
analyses confirmed the efficacy of methylnaltrexone52,53 and suggested that it may be 262 
particularly effective in those patients taking large daily opioid doses. Rauck et al 263 
reported that gastrointestinal side effects with oral methylnaltrexone occurred at the same 264 
rate as in the placebo group,18 which did not appear to be the case with the subcutaneous 265 
formulation.17,39 This should be considered when choosing between the two formulations, 266 
although this finding needs additional confirmatory studies.  267 
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 Although alvimopan was studied in the setting of OIC, it is approved only for the 268 
treatment of POI in hospitalized patients who have undergone partial small or large 269 
bowel resection surgery.54 This is reflected by the existence of fewer studies for 270 
alvimopan in OIC and the lack of recent, late-phase studies and post-hoc analyses. As 271 
stated by Irving et al, “alvimopan was under clinical development for long-term treatment 272 
of opioid-induced constipation but this program has been discontinued.”33 Concerns by 273 
the Food and Drug Administration over the “imbalance” in the number of cardiovascular 274 
events (more myocardial infarctions) in the alvimopan group versus placebo group 275 
prompted the discontinuation of the OIC program and limited its approved indication to 276 
inpatient use only.55 Positive results in one of the two replicate Phase 3 studies32 but not 277 
the other33 speak to the lack of evidence for a specific dose and inconsistent study design 278 
between these and an earlier Phase 2 study.34  279 
 Naloxegol, the newest PAM-OR antagonist in the group, has demonstrated 280 
positive results in both studies in this review and agrees with the findings of other 281 
reviews.19 Leppart and Woron reported that naloxegol was effective in up to 49% of 282 
patients not responsive to standard laxatives and that naloxegol has been shown to be 283 
more effective than placebo in patients with OIC and noncancer pain. No studies have 284 
been performed in cancer patients.19 The approved dose is 25 mg.16 Comparison of 285 
naloxegol to oral methylnaltrexone is difficult because the primary endpoints are not the 286 
same from the published studies. However, the available data suggest that while both 287 
agents are effective, adverse effects occurred at a greater frequency with naloxegol 288 
compared to placebo41,42 while patients who received oral methylnaltrexone had a similar 289 
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rate of adverse effects as the placebo group.18 Although confirmatory studies are needed, 290 
this suggests oral methylnaltrexone may have a superior side-effects profile. 291 
 For POI, the only PAM-OR antagonist FDA-approved for this indication is 292 
alvimopan. Heterogeneity in endpoints was a problem throughout the literature with most 293 
studies using some composite form of return to GI function. When given preoperatively 294 
and continued postoperatively, we found that alvimopan is effective in reducing POI. An 295 
important exclusion in many of the studies was opioid use prior to surgery. This could 296 
limit the number of patients who can receive alvimopan.  297 
 Viscusi et al reported that both methylnaltrexone and alvimopan do not cross the 298 
blood brain barrier for different reasons: for methylnaltrexone, this is due to its polarity 299 
and low lipid solubility that results from the addition of a fourth methyl group to 300 
naltrexone, making it a quaternary structure; for alvimopan, this is due its high polarity as 301 
a zwitterion.7 Our review included three additional alvimopan studies and one additional 302 
methylnaltrexone study not included in theirs. We found no evidence for reversal of 303 
opioid-mediated analgesia, although one study did not include any measurements.51 304 
 Methylnaltrexone studies for POI had conflicting evidence in this review. In the 305 
two studies that evaluated it in this context,26,51 the IV formulation was given 306 
postoperatively. It should be noted that the study that reported positive results enrolled 65 307 
patients, while the study that found no improvement with methylnaltrexone was actually 308 
the results of two identical studies with n=515 and n=533. 309 
 It should be noted that three alvimopan studies45,47,50 and one methylnaltrexone51 310 
POI study specified that they did not allow epidural analgesia in the protocols, which is 311 
understandable given the existing evidence for epidurals.56 In the other POI studies it was 312 
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not stated whether epidural analgesia was excluded. In a multimodal or enhanced 313 
recovery after surgery (ERAS) pathway involving epidural analgesia, the duration of 314 
ileus in the placebo group would likely be shorter. Similarly, intravenous lidocaine has 315 
been shown to reduce duration of ileus and this was excluded from the studies as well.57 316 
Therefore, clinicians should consider this when evaluating the potential improvement in 317 
POI duration that a PAM-OR antagonist may produce. 318 
 Comparative-effectiveness studies in this field are clearly needed.  None of the 319 
studies included in this review compared one PAM-OR antagonist to another. This makes 320 
direct comparisons difficult especially when heterogeneity in endpoints for the individual 321 
studies is taken into account. In addition, laxatives were permitted in some studies and 322 
not others, further complicating the picture. Although we did not analyze medication cost 323 
in this review, these charges as well as insurance coverage are additional considerations 324 
that may affect choice of agent. 325 
  This review has some limitations. We were unable to determine if there were 326 
unpublished studies that did not show positive results, and it is possible that some of 327 
these stopped prematurely. This may be particularly true with alvimopan, which was 328 
studied for OIC and subsequently abandoned for that indication. Second, there may be 329 
some studies that were not located through our search protocols. We attempted to 330 
minimize this limitation by combining two search databases, using two reviewers, and 331 
using as broad of a selection of search terms as feasible. However, studies with different 332 
key words or search terms could have been omitted. 333 
  334 
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Conclusion 335 
In conclusion, PAM-OR antagonists may be effective in both OIC and POI but 336 
the inconsistency of study design, study endpoints, and lack of comparative studies limits 337 
the strength of our recommendations. Within the class methylnaltrexone has the most 338 
consistent evidence, and its oral formulation may be slightly less effective than the 339 
subcutaneous formulation but cause fewer gastrointestinal adverse effects. Although 340 
naloxegol is more effective than placebo for OIC, it appears to cause more adverse 341 
effects than oral methylnaltrexone. Alvimopan is the only FDA-approved and most well-342 
studied agent for POI. Comparative studies are lacking. A multimodal treatment strategy 343 
for OIC and POI is recommended for these multifactorial disease states and evaluation of 344 
these agents combined with epidural analgesia and intravenous lidocaine is needed. 345 
Additional PAM-OR antagonists are currently under development but the potential 346 
market for these agents may become smaller as efforts to fight the opioid epidemic 347 
intensify.  348 
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